Cejuela, M., Gil-Torralvo, A., Castilla, M. Á., Domínguez, M. Á., Falcón, A., Benavent, M., . . . Salvador-Bofill, J. (2023). Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer.
Citación estilo ChicagoCejuela, Mónica, Ana Gil-Torralvo, María Ángeles Castilla, María Ángeles Domínguez, Alejandro Falcón, Marta Benavent, Sonia Molina-Pinelo, Manuel Ruiz-Borrego, y Javier Salvador-Bofill. Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. 2023.
Cita MLACejuela, Mónica, et al. Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. 2023.